Document is current
Any future updates will be listed below
-
Authors
Kwatra, Shawn G.
Yang, Min
Martins, Bruno
Zion, Abigail
Liu, Jingyi
Zahn, Joseph
Ozarslan, Bengisu
Bahloul, Donia
Payan, Marine
Thomas, Ryan B. https://orcid.org/0000-0002-1141-2073
-
Funding
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
- License Information
-
More Information
Article History
Received: 24 February 2025
Accepted: 22 April 2025
First Online: 29 May 2025
Declarations
:
: Shawn G Kwatra—AbbVie, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte, Johnson & Johnson, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi—advisory board member/consultant; Galderma, Incyte, Pfizer, Sanofi—investigator. Min Yang, Bruno Martins, Abigail Zion, and Jingyi Liu—employees of Analysis Group and may hold stocks and/or stock options in the company; Joseph Zahn, and Ryan B Thomas—employees of Regeneron Pharmaceuticals Inc. and may hold stocks and/or stock options in the company; Bengisu Ozarslan, Donia Bahloul, Marine Payan—employees of Sanofi and may hold stocks and/or stock options in the company.
: The study was conducted in accordance with the Declaration of Helsinki. The study was exempted from needing ethical approval by the Pearl Local Ethics Committee (according to FDA 21 CFR 56.104 and 45 CFR46.104(b)(2): (2) Tests, Surveys, Interviews). Informed consent to participate and consent for publication were obtained from all participants before study enrolment.
